Saved in:
| Main Author: | |
|---|---|
| Format: | Recurso digital |
| Language: | |
| Published: |
Zenodo
2025
|
| Online Access: | https://doi.org/10.5281/zenodo.14635746 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Table of Contents:
- <p>The high rate of brain metastasis in patients with non-small cell and small cell lung cancer demands discovery of novel therapeutic targets to treat lymph node metastasis which serves as an intermediate to the CNS (central nervous system) (1-5). We recently utilized whole transcriptome technologies to define the full complement of differentially expressed kinases and phosphatases in HER2+ breast cancer: in the primary tumor, and in metastasis to the CNS (6-8). Here we utilize whole transcriptome technologies (9, 10) to measure total transcription in the lymph node metastases of humans with small cell and non-small cell lung cancer. We describe here a therapeutic target that is up-regulated and differentially expressed in lymph node metastasis in humans with small cell and non-small cell lung cancer, BAALC, as a candidate therapeutic target for the medical management of lymph node metastasis in human lung cancer. </p>